v3.25.2
Segment Information (Tables)
 3 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The Company’s significant segment expenses are as follows (in thousands):

Three months ended June 30,
20252024
Therapeutic area-specific research and development:
Endocrine diseases$19,329 $15,913 
Neurological diseases20,937 18,479 
Rheumatology diseases8,209 — 
Dermatology diseases5,145 — 
Other clinical and nonclinical2,392 6,401 
Other unallocated research and development10,685 10,160 
Personnel-related research and development (1)
34,503 24,520 
Personnel-related general and administrative (2)
17,832 10,696 
Other general and administrative (3)
8,192 8,112 
Interest income, net(6,337)(7,180)
Other segment items (4)
(274)49 
Net loss$120,613 $87,150 
___________
(1)Includes stock-based compensation expense of $7,865 and $7,185 for the three months ended June 30, 2025 and 2024, respectively.
(2)Includes stock-based compensation expense of $10,645 and $6,270 for the three months ended June 30, 2025 and 2024, respectively.
(3)Other general and administrative expenses primarily include legal and other professional fees, information technology costs and market research costs.
(4)Other segment items include other expense (income), net and provision (benefit) for income taxes.